CRISPR comes of age years ahead of schedule with first diagnostic authorization
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
FDA’s authorization of a CRISPR-based diagnostic for COVID-19 from Sherlock Biosciences is another step in the right direction for COVID-19 diagnostics, but it’s a much bigger win for the CRISPR technology.
It represents the first time a CRISPR-based product has been authorized for use in healthcare, and it comes years before anyone was expecting it.
“This authorization has propelled CRISPR into healthcare,” said Rahul Dhanda, CEO of Sherlock Biosciences Inc., the diagnostics company tied to CRISPR IP from the Broad Institute of MIT and Harvard. “Most people think of CRISPR as